Literature DB >> 18317564

The comeback kid: TYSABRI now FDA approved for Crohn disease.

Karen Honey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18317564      PMCID： PMC2254986          DOI： 10.1172/JCI35179

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  3 in total

1.  Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.

Authors:  Annette Langer-Gould; Scott W Atlas; Ari J Green; Andrew W Bollen; Daniel Pelletier
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

2.  Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.

Authors:  Gert Van Assche; Marc Van Ranst; Raf Sciot; Bénédicte Dubois; Séverine Vermeire; Maja Noman; Jannick Verbeeck; Karel Geboes; Wim Robberecht; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

3.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Authors:  Chris H Polman; Paul W O'Connor; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; David H Miller; J Theodore Phillips; Fred D Lublin; Gavin Giovannoni; Andrzej Wajgt; Martin Toal; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245
  3 in total
  7 in total

Review 1.  Update on the management of Crohn's disease.

Authors:  Anna M Buchner; Wojciech Blonski; Gary R Lichtenstein
Journal:  Curr Gastroenterol Rep       Date:  2011-10

Review 2.  A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD.

Authors:  Kenechukwu O Chudy-Onwugaje; Kaci E Christian; Francis A Farraye; Raymond K Cross
Journal:  Inflamm Bowel Dis       Date:  2019-04-11       Impact factor: 5.325

Review 3.  A look at autoimmunity and inflammation in the eye.

Authors:  Rachel R Caspi
Journal:  J Clin Invest       Date:  2010-09-01       Impact factor: 14.808

4.  Natural History of New-onset Inflammatory Bowel Disease Among Patients With Multiple Sclerosis.

Authors:  Shiv Gandhi; Sara Zelman; Ricardo Eduardo De Armas; Christopher Hemond; Alexander N Levy; Siddharth Singh; Joshua Korzenik; Sushrut Jangi
Journal:  Inflamm Bowel Dis       Date:  2022-10-03       Impact factor: 7.290

Review 5.  The current state of the art for biological therapies and new small molecules in inflammatory bowel disease.

Authors:  Sudarshan Paramsothy; Adam K Rosenstein; Saurabh Mehandru; Jean-Frederic Colombel
Journal:  Mucosal Immunol       Date:  2018-06-15       Impact factor: 7.313

Review 6.  Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges.

Authors:  Marcel Vetter; Markus F Neurath
Journal:  Therap Adv Gastroenterol       Date:  2017-09-05       Impact factor: 4.409

7.  Natalizumab in Crohn's disease: past and future areas of applicability.

Authors:  Alessandro Armuzzi; Carla Felice
Journal:  Ann Gastroenterol       Date:  2013
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.